Daytrading, Eminis, Forex trading, Swing Trading BREAKING NEWS - 489804
Travis Roy  |  by www.tradingmarkets.com. All rights reserved. 13.11 | 23:23

Receive Dave's best setups each evening from his favorite trading patterns.

Let Gary Kaltbaum send you timely emails to alrt when breakouts occure.
Every day receive the best plan of attack for the next day's trading directly from professional trader Kevin Haggerty.

(RTTNews) - Thursday, ZIOPHARM Oncology, Inc. ( | | | ) revealed the presentation of new mechanism data that further differentiates ZIO-101, a novel organic arsenic, from inorganic arsenic by Dr. Taghi Manshouri of the University of Texas M.

D. Anderson Cancer Center. The company noted that the mechanism data indicate that certain cancer cells resistant to inorganic arsenic are sensitive to ZIO-101.

ZIO-101 clinical data would be the subject of a separate presentation at the 18th EORTC-NCI-AACR Symposium on "Molecular Targets, and Cancer Therapeutics" meeting on November 10th. Dr. Manshouri's data show that the major intra-cellular target of arsenic is the mitochondria, an organelle responsible for the energy charge of the cell, whose disruption leads to apoptosis and cell death, said the company.

Based on this mechanism ZIO-101 induces more cancer cell killing than inorganic arsenic. The company further added that preliminary data from the study suggest that different genes are regulated by ZIO-101 than inorganic arsenic.

Read more on by www.tradingmarkets.com. All rights reserved.
Related news
Post comments
Name
Place
2 + 4 =
Comments